Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2017 /
New drug advancements presented at ASCO

14th - 16th Jul 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.07.17
Views: 1311

Dr Christian Rolfo – Antwerp University, Belgium

Dr Rolfo talks with ecancer at the Best of ASCO 2017 meeting in Miami about new drug advancements that were presented at the ASCO annual meeting. He discusses the new NTRK inhibitor, larotrectinib, which is yielding a 76% response rate and a 12% complete response rate with patients.

He goes on to talk about new combinations on the horizon for immunotherapy and drugs for a variation of tumour types.

Dr Philip talked about new drugs that are in development for pancreatic cancer here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation